SCHEMBL6691336

SCHEMBL6691336

CC(=O)Nc1ccc(-c2sccc2NS(=O)(=O)c2ccc(-c3ccccc3)cc2)cc1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 1/20 0.57
MEN1 O00255 2/20 0.55
KMT2A Q03164 2/20 0.55
GAA P10253 1/20 0.55
GFER P55789 1/20 0.55
BDKRB1 P46663 5/20 0.55
KDM4E B2RXH2 1/20 0.52
CKS1B P61024 1/20 0.52
SKP2 Q13309 1/20 0.52
CA2 P00918 2/20 0.50
CA1 P00915 1/20 0.50
MMP1 P03956 1/20 0.50
MMP2 P08253 1/20 0.50
MMP9 P14780 1/20 0.50
MMP8 P22894 1/20 0.50
MMP13 P45452 1/20 0.50
IDO1 P14902 1/20 0.50
AKT1 P31749 1/20 0.49
PKM P14618 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6612502 0.86 MEN1 (0.56) HTTMEN1KMT2AGAACA2
SCHEMBL6614571 0.84 MEN1 (0.50) HTTMEN1KMT2ACA2CA1
SCHEMBL6610826 0.81 ATM (0.65) HTTMEN1KMT2AGAABDKRB1
SCHEMBL6694347 0.79 CKS1B (0.60) HTTMEN1KMT2AGAAGFER
SCHEMBL7560628 0.78 LMNA (0.63) MEN1KMT2AGAAKDM4EL3MBTL1
SCHEMBL6623115 0.77 ATM (0.51) HTTMEN1KMT2ABDKRB1IDO1
SCHEMBL6612970 0.77 PIK3CD (0.43) HTTMEN1KMT2AGAAIDO1
SCHEMBL7531331 0.77 DHODH (0.55) HTTMEN1KMT2AGAAKDM4E
SCHEMBL3402411 0.75 MEN1 (0.91) MEN1KMT2AGAAGFERBDKRB1
SCHEMBL2762864 0.75 MAPT (0.77) HTTMEN1KMT2AGAAGFER

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US claimed
WO-2004112779-A1 NEW USE VII BIOVITRUM AB (SE) 2004-12-29 WO disclosed
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 BIOVITRUM AB (SE) 2003-07-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030130279-A1 Inhibitors of 11-beta-hydroxy steroid dehydrogenase type 1 HSD11B1, HSD17B1, HSD3B1 HTT 3401/4885MEN1 770/4885KMT2A 3247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.